Nerve regeneration gene therapy - Oxford Biomedica

Drug Profile

Nerve regeneration gene therapy - Oxford Biomedica

Alternative Names: Innurex; RARβ2 gene therapy - Oxford BioMedica

Latest Information Update: 09 Dec 2010

Price : $50

At a glance

  • Originator Oxford BioMedica
  • Class Gene therapies
  • Mechanism of Action Gene transference; Neuron stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Spinal cord injuries

Most Recent Events

  • 28 Aug 2007 The nerve regeneration gene therapy is still in preclinical development for spinal cord injury in the UK
  • 23 Jun 2005 Data presented at the 8th Annual Meeting of the American Society of Gene Therapy (ASGT-2005) have been added to the Neurological Disorders pharmacodynamics section
  • 09 Jun 2005 Preclinical data from a media release have been added to the Neurological disorders pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top